Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?
European Respiratory Journal,
Journal Year:
2023,
Volume and Issue:
62(2), P. 2300700 - 2300700
Published: July 20, 2023
Several
current
guidelines/strategies
outline
a
treatment
approach
to
asthma,
which
primarily
consider
the
goals
of
improving
lung
function
and
quality
life
reducing
symptoms
exacerbations.
They
suggest
strategy
stepping
up
or
down
treatment,
depending
on
patient's
overall
asthma
symptom
control
future
risk
exacerbation.
While
this
stepwise
is
undeniably
practical
for
daily
practice,
it
does
not
always
address
underlying
mechanisms
heterogeneous
disease.
In
last
decade,
there
have
been
attempts
improve
severe
such
as
addition
long-acting
antimuscarinic
agent
traditional
inhaled
corticosteroid/long-acting
β2-agonist
introduction
therapies
targeting
key
cytokines.
However,
despite
strategies
several
unmet
needs
in
population
remain,
motivating
research
identify
novel
targets
develop
improved
therapeutic
and/or
preventative
treatments.
Pending
availability
therapies,
essential
re-evaluate
conventional
"one-size-fits-all"
more
precise
management.
Although
challenging,
identifying
"treatable
traits"
that
contribute
respiratory
individual
patients
with
may
allow
pragmatic
establish
personalised
goals.
Language: Английский
COPD: Providing the right treatment for the right patient at the right time
Respiratory Medicine,
Journal Year:
2022,
Volume and Issue:
207, P. 107041 - 107041
Published: Dec. 10, 2022
Language: Английский
Efficacy and safety of once-daily single-inhaler triple therapy for mild-to-moderate chronic obstructive pulmonary disease: a study protocol for a randomised and interventional study
BMJ Open Respiratory Research,
Journal Year:
2023,
Volume and Issue:
10(1), P. e001607 - e001607
Published: May 1, 2023
Bronchodilators,
including
long-acting
muscarinic
antagonists
(LAMA)
and
beta
2
agonists
(LABA),
are
the
main
treatments
for
chronic
obstructive
pulmonary
disease
(COPD).
The
efficacy
of
triple
therapy
(inhaled
corticosteroids/LAMA/LABA)
has
also
been
reported.
However,
effect
on
patients
with
mild-to-moderate
COPD
not
yet
clarified.
This
study
aims
to
investigate
safety
therapy,
compared
LAMA/LABA
combination
lung
function
health-related
quality
life
in
identify
baseline
characteristics
biomarkers
predict
responders
non-responders
therapy.This
is
a
multicentre,
prospective,
open-label,
randomised,
parallel-group
study.
Mild-to-moderate
will
be
randomised
receive
fluticasone
furoate/umeclidinium/vilanterol
or
umeclidinium/vilanterol
24
weeks.
A
total
668
enrolled
from
March
2022
September
2023
38
sites
Japan.
primary
endpoint
change
trough
forced
expiration
volume
1
s
after
12
weeks
treatment.
Secondary
endpoints
responder
rates
based
assessment
test
score
St.
George's
Respiratory
Questionnaire
occurrence
any
adverse
events.
We
terms
changes
microbial
colonisation
sputum
antimycobacterium
avium
complex
antibodies.The
protocol
informed
consent
documents
were
approved
by
Saga
University
Clinical
Research
Review
Board
(approval
number:
CRB7180010).
Written
obtained
all
patients.
Recruitment
began
2022.
results
disseminated
through
scientific
peer-reviewed
publications
domestic
international
medical
conferences.UMIN000046812
jRCTs031190008.
Language: Английский
Effect of budesonide formoterol combined with tiotropium bromide on pulmonary function and inflammatory factors in patients with asthma–COPD overlap syndrome
Allergologia et Immunopathologia,
Journal Year:
2023,
Volume and Issue:
51(4), P. 131 - 138
Published: July 1, 2023
To
investigate
the
clinical
efficacy
of
combining
budesonide
formoterol
with
tiotropium
bromide
for
treating
asthma-chronic
obstructive
pulmonary
disease
overlap
syndrome
(AOCS).The
data
104
patients
AOCS
admitted
to
our
hospital
from
December
2019
2020
were
assessed,
randomly
and
divided
into
an
experimental
group
(comprising
52
patients,
receiving
drug
combination
therapy)
a
conventional
therapy
alone).
Patients'
efficacy,
function,
fractioned
exhaled
nitric
oxide
(FeNO),
immune
endothelial
serum
lipid
peroxidation
injury
indexes,
adverse
reactions,
quality
life
scores
compared.Prior
treatment,
no
significant
differences
observed
in
various
function
indicators,
FeNO,
indexes
between
two
groups
(P
>
0.05).
However,
after
all
observation
both
improved
different
levels,
-demonstrating
-significantly
superior
improvement,
compared
<
We
also
that
reactions
significantly
lower
than
0.05).The
asthma-COPD
may
improve
status
encourage
recovery
injury;
therefore,
this
deserve
widespread
adoption
application.
Language: Английский
Medication adherence in Medicare-enrolled older adults with asthma and chronic obstructive pulmonary disease before and during COVID-19 pandemic
Therapeutic Advances in Chronic Disease,
Journal Year:
2023,
Volume and Issue:
14
Published: Jan. 1, 2023
Medication
adherence
in
Medicare-enrolled
older
adults
with
asthma
and
chronic
obstructive
pulmonary
disease
(COPD)
before
during
the
coronavirus
2019
(COVID-19)
pandemic
is
unknown.To
evaluate
medication
determinants
of
high
COVID-19
this
population.Retrospective
cohort
study.The
proportion
days
covered
(PDC)
reflected
from
January
to
July
2020.
Patients
<65
years
age,
COPD
or
alone,
cystic
fibrosis
were
excluded.
Paired
t
tests
used
assess
changes.
Logistic
regression
explored
association
sex,
diagnosis
depression,
number
medications,
medication-related
problems,
prescribers,
pharmacies,
controller
classes,
albuterol
rescue
inhaler
fills,
oral
corticosteroid
having
a
90-day
supply
(PDC
⩾
80%).This
analysis
included
989
patients.
In
cohort,
61.2%
patients
received
corticosteroids.
Over
60%
had
⩾3
fills
both
medications
significantly
decreased
for
all
(p
<
0.001)
2020,
classes
associated
0.001).
2019,
variables
also
problems
inhalers
0.001).Medication
controllers
among
COPD.
multiple
more
likely
be
highly
adherent.
A
should
facilitate
access
pandemic.
Healthcare
professionals
adherence,
resolve
barriers
achieve
desired
clinical
outcomes
Language: Английский